What stands out as a possible new cancer target to therapeutically drug?

Every year as part of our AACR Preview series, I pick a novel target to illustrate where innovative ideas are coming to the fore based on new and often early scientific evidence.

There is also the hope they might lead to future clinical drug development and emerging pipelines.

Some of these targets can turn out to be tough to drug for various reasons, including narrow therapeutic windows limiting the dosing schedule that can be realistically achieved (bromodomains come to mind), while others lead to some intriguing compounds which end up going further than expected.

Here’s the sixth article in this year’s series where we identify and discuss an early novel target of interest…

To learn more about the AACR21 data and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by